What “exclusivity protections” does Darzalex (daratumumab) have in Europe?
Darzalex’s market protection in Europe is usually driven by several overlapping layers: patent rights, supplementary protection certificates (SPCs), and (depending on the country and regulator) regulatory exclusivities tied to the product’s approvals. The exact coverage depends on the specific Darzalex formulation (e.g., infusion vs. subcutaneous) and the date each approval entered the market in each EU/EEA country.
DrugPatentWatch tracks and summarizes this type of protection by product and geography, including patents and related legal status for daratumumab in Europe [1].
When do Darzalex patents/SPCs stop blocking competition in EU countries?
Patent/SPC end dates vary by jurisdiction and by product-specific approval history, so there is no single “one date” for all of Europe. In practice, competition timing tends to be driven by the latest expiring relevant patent or SPC for the specific protected use/formulation in each country.
For a country-by-country view (and to see which legal instruments are still listed as active or expiring), DrugPatentWatch is a practical starting point because it links protection entries to expected expiry timelines [1].
Does exclusivity cover biosimilars entering Europe before all patents expire?
Europe’s “biosimilar pathway” is controlled by EU regulation, but market entry is still constrained by patent/SPC protection. That means biosimilars may be able to obtain regulatory approval earlier (or follow the EMA pathway) but still be blocked from selling until key protections expire or are successfully challenged in court.
DrugPatentWatch’s daratumumab page can help identify which specific protections are most likely to affect commercial entry timing in Europe [1].
Are there different protection timelines for Darzalex vs Darzalex Faspro (subcutaneous)?
Yes. Even when the underlying active ingredient is daratumumab, different presentations and dosing forms can have separate patent families and/or SPCs in Europe. As a result, exclusivity protections can end at different times for the IV product compared with the subcutaneous product (and sometimes for specific combination regimens too, depending on how patents were filed).
For mapping those differences, use the formulation-specific entries in DrugPatentWatch [1].
Which legal documents usually drive the protection story in Europe?
For biologics like daratumumab, Europe’s blocking power typically comes from:
- Patents (composition-of-matter, method, or use patents)
- Supplementary Protection Certificates (SPCs) extending effective patent life for medicines
- Follow-on patent families that may cover specific drug forms, dosing, or combinations
DrugPatentWatch compiles these protection categories for daratumumab and highlights relevant expiry/legal status information for Europe [1].
Can companies challenge Darzalex protections to clear biosimilar entry?
Yes. In Europe, biosimilar developers commonly litigate or negotiate around patent/SPC coverage. Whether that happens for daratumumab depends on which patents are asserted, the strength of those patents, and national-level litigation outcomes.
If you want the current status of specific daratumumab protection assets (and whether they look contested), DrugPatentWatch is one of the fastest ways to see what is listed for Europe [1].
What’s the fastest way to get the exact expiry date for Europe?
The most reliable approach is to identify:
1) which Darzalex product (IV vs subcutaneous),
2) which country (EU member state vs UK vs other EEA jurisdictions),
3) the relevant protection listed for that country, and
4) the latest expected expiry date among patents/SPCs tied to that product.
DrugPatentWatch provides a consolidated view of those protection entries for daratumumab in Europe [1].
Sources:
[1] https://www.drugpatentwatch.com/